105 related articles for article (PubMed ID: 23312474)
1. Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
Sidduri A; Tilley JW; Lou J; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1026-31. PubMed ID: 23312474
[TBL] [Abstract][Full Text] [Related]
2. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
Tilley JW; Sidduri A; Lou J; Kaplan G; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1036-40. PubMed ID: 23312471
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
[TBL] [Abstract][Full Text] [Related]
4. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist.
Chanteux H; Staelens L; Mancel V; Gerin B; Boucaut D; Prakash C; Nicolas JM
Drug Metab Dispos; 2015 Sep; 43(9):1381-91. PubMed ID: 26153275
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
[TBL] [Abstract][Full Text] [Related]
6. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist.
Sircar I; Gudmundsson KS; Martin R; Liang J; Nomura S; Jayakumar H; Teegarden BR; Nowlin DM; Cardarelli PM; Mah JR; Connell S; Griffith RC; Lazarides E
Bioorg Med Chem; 2002 Jun; 10(6):2051-66. PubMed ID: 11937364
[TBL] [Abstract][Full Text] [Related]
8. N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Hutchinson B; Parton TA; Robinson MK; Shock A; Warrellow GJ; Zomaya A
Bioorg Med Chem Lett; 2002 Jun; 12(12):1595-8. PubMed ID: 12039570
[TBL] [Abstract][Full Text] [Related]
9. In vitro hydrolysis and transesterification of CDP323, an α4β1/α4β7 integrin antagonist ester prodrug.
Chanteux H; Rosa M; Delatour C; Prakash C; Smith S; Nicolas JM
Drug Metab Dispos; 2014 Jan; 42(1):153-61. PubMed ID: 24179032
[TBL] [Abstract][Full Text] [Related]
10. N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.
Chen L; Tilley JW; Huang TN; Miklowski D; Trilles R; Guthrie RW; Luk K; Hanglow A; Rowan K; Schwinge V; Wolitzky B
Bioorg Med Chem Lett; 2000 Apr; 10(8):725-7. PubMed ID: 10782673
[TBL] [Abstract][Full Text] [Related]
11. Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.
Dyatkin AB; Gong Y; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Hornby PJ; Diamond C; Kinney WA; Maryanoff BE; Damiano BP; He W
Bioorg Med Chem; 2005 Dec; 13(24):6693-702. PubMed ID: 16112583
[TBL] [Abstract][Full Text] [Related]
12. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
[TBL] [Abstract][Full Text] [Related]
13. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.
Cortijo J; Sanz MJ; Iranzo A; Montesinos JL; Nabah YN; Alfón J; Gómez LA; Merlos M; Morcillo EJ
Br J Pharmacol; 2006 Mar; 147(6):661-70. PubMed ID: 16432509
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.
Gong Y; Kent Barbay J; Kimball ES; Santulli RJ; Carolyn Fisher M; Dyatkin AB; Miskowski TA; Hornby PJ; He W
Bioorg Med Chem Lett; 2008 Feb; 18(4):1331-5. PubMed ID: 18226905
[TBL] [Abstract][Full Text] [Related]
16. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.
Li B; de Laszlo SE; Kamenecka TM; Kopka IE; Durette PL; Lanza T; MacCoss M; Tong S; Mumford RA; McCauley ED; Van Riper G; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Aug; 12(16):2141-4. PubMed ID: 12127523
[TBL] [Abstract][Full Text] [Related]
17. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ
Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895
[TBL] [Abstract][Full Text] [Related]
18. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
Vanderslice P; Woodside DG; Caivano AR; Decker ER; Munsch CL; Sherwood SJ; Lejeune WS; Miyamoto YJ; McIntyre BW; Tilton RG; Dixon RA
Biochem Biophys Res Commun; 2010 Oct; 400(4):619-24. PubMed ID: 20807504
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
[TBL] [Abstract][Full Text] [Related]
20. N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.
Gutteridge CE; de Laszlo SE; Kamenecka TM; McCauley E; van Riper G; Mumford RA; Kidambi U; Egger LA; Tong S; Hagmann WK
Bioorg Med Chem Lett; 2003 Mar; 13(5):885-90. PubMed ID: 12617914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
